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ABSTRACT
Objective: The reported association between
calibrated integrated backscatter (cIB) and myocardial
fibrosis is based on study of patients with dilated or
hypertrophic cardiomyopathy and extensive (mean
15–34%) fibrosis. Its association with lesser degrees
of fibrosis is unknown. We examined the relationship
between cIB and myocardial fibrosis in patients with
coronary artery disease.
Methods: Myocardial histology was examined in left
ventricular epicardial biopsies from 40 patients (29
men and 11 women) undergoing coronary artery
bypass graft surgery, who had preoperative
echocardiography with cIB measurement.
Results: Total fibrosis (picrosirius red staining) varied
from 0.7% to 4%, and in contrast to previous reports,
cIB showed weak inverse associations with total
fibrosis (r=−0.32, p=0.047) and interstitial fibrosis
(r=−0.34, p=0.03). However, cIB was not significantly
associated with other histological parameters,
including immunostaining for collagens I and III, the
advanced glycation end product (AGE)
Nε-(carboxymethyl)lysine (CML) and the receptor for
AGEs (RAGE). When biomarkers were examined, cIB
was weakly associated with log plasma levels of
amino-terminal pro-B-type natriuretic peptide (r=0.34,
p=0.03), creatinine (r=0.33, p=0.04) and glomerular
filtration rate (r=−0.33, p=0.04), and was more
strongly associated with log plasma levels of soluble
vascular endothelial growth factor receptor-1 (sVEGFR-
1) (r=0.44, p=0.01) and soluble RAGE (r=0.53,
p=0.002).
Conclusions: Higher cIB was not a marker of
increased myocardial fibrosis in patients with coronary
artery disease, but was associated with higher plasma
levels of sVEGFR-1 and soluble RAGE. The role of cIB
as a non-invasive index of fibrosis in clinical studies of
patients without extensive fibrosis is, therefore,
questionable.
INTRODUCTION
Researchers and clinicians need a method to
identify and quantify the extent of myocar-
dial ﬁbrosis throughout all stages of myocar-
dial disease, so that they can study
longitudinal changes in myocardial ﬁbrosis
and measure the effects of novel antiﬁbrotic
therapies, particularly in the early stages of
the disease when changes may be more likely
to be reversible. One non-invasive approach
to measurement of myocardial ﬁbrosis has
been the echocardiographic measurement of
calibrated integrated backscatter (cIB).1–7
cIB is a measure of the ultrasonic reﬂectiv-
ity of the myocardium relative to the high
reﬂectivity of the pericardium and the low
reﬂectivity of blood. cIB is correlated with
histologically measured myocardial ﬁbrosis in
patients with dilated or hypertrophic cardio-
myopathy and extensive ﬁbrosis (mean 15–
34% ﬁbrosis),1–5 and it has been applied to
the non-invasive assessment of myocardial
ﬁbrosis in a broad spectrum of patients,
including those with the metabolic syndrome
KEY QUESTIONS
What is already known about this subject?
▸ Increased calibrated integrated backscatter (cIB)
is associated with increased myocardial fibrosis
in patients with dilated or hypertrophic cardio-
myopathy and extensive (mean 15–34%) fibro-
sis. However, its association with lesser degrees
of fibrosis is unknown.
What does this study add?
▸ This is the first study to examine the relationship
between cIB and myocardial fibrosis in patients
with lesser degrees of fibrosis (0.7–4%). A key
novel finding was that increased cIB was not
associated with increased myocardial fibrosis,
but was associated with higher plasma levels of
soluble vascular endothelial growth factor
receptor-1 and soluble receptor for advanced
glycation end products.
How might this impact on clinical practice?
▸ These data question whether cIB is a reliable
non-invasive index of fibrosis in clinical studies
of patients without extensive fibrosis.
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and type 2 diabetes.6 7 Moreover, some authors have
interpreted the association of cIB with left ventricular
functional abnormalities as evidence for the contribu-
tion of myocardial ﬁbrosis to these abnormalities.6 7
There is, however, uncertainty about the relationship
between cIB and ﬁbrosis in patients with less extensive
ﬁbrosis. We have shown that left ventricular functional
abnormalities of the metabolic syndrome and type 2 dia-
betes are not associated with increased myocardial ﬁbro-
sis.8 In addition, factors other than ﬁbrosis may
inﬂuence cIB.9–16 cIB increases in response to acute
myocardial ischaemia9 and mild or greater degrees of
acute cardiac allograft rejection,10 and is associated with
serum levels of the angiogenesis-related biomarker
interleukin-13 (IL-13).11 In patients with chronic renal
failure, cIB is correlated with serum creatinine12 and is
reduced by increased hours/week of dialysis over 12
months,13 but not by a single dialysis session.14 In add-
ition, cIB is increased in overweight individuals15 and
reduced by weight loss.16 Of note is the lack of correl-
ation between cIB and T1 mapping techniques of
cardiac MRI that have been proposed as an alternative
measure of myocardial ﬁbrosis.17
Given the uncertain relationship between cIB and
myocardial ﬁbrosis in patients without extensive ﬁbrosis,
we examined the relationship between cIB, myocardial
ﬁbrosis, clinical parameters and plasma levels of
angiogenesis-related biomarkers in patients undergoing
coronary artery bypass graft (CABG) surgery, who did
not have dilated or hypertrophic cardiomyopathy.
METHODS
Patient population and data collection
The population consisted of all patients undergoing
CABG surgery recruited to the St. Vincent’s Hospital
Melbourne Cardiac Tissue Bank who did not have heart
failure or atrial ﬁbrillation, had a relatively preserved left
ventricular systolic function, and had a detailed echocar-
diographic examination, including cIB measurement, a
few days before surgery. Details of the Tissue Bank are
described elsewhere.18 From each patient recruited to
the Tissue Bank, an epicardial partial-thickness wedge-
shaped biopsy was taken immediately after cardioplegia
from a region in the lateral wall of the left ventricle near
the base of the heart, between the territories of the left
anterior descending and circumﬂex arteries that was
free of any macroscopic pathology, and without evidence
of ischaemia or wall motion abnormality on preoperative
or intraoperative imaging studies. None of the patients
had dilated or hypertrophic cardiomyopathy. This study
was approved by St. Vincent’s Hospital Melbourne
Human Research Ethics Committee and conforms to
the principals outlined in the Declaration of Helsinki.
Each participant provided written informed consent.
Details of haemodynamic measurements, and bio-
chemical and histological methods are described in the
online supplementary data.
Echocardiographic evaluation
All echocardiographic analyses were performed by the
same individual who was blinded to myocardial histology,
haemodynamic data and angiogenesis-related biomarker
levels.
Transthoracic echocardiograms were performed with
patients in the left lateral position using a VIVID 7 echo-
cardiograph (GE Medical, Milwaukee, Wisconsin, USA).
Routine M-mode, two-dimensional and Doppler images
were acquired, and all images were stored in digital raw
data format for subsequent ofﬂine analysis using com-
mercially available software (EchoPAC PC, GE, Horten,
Norway). All patients were in sinus rhythm and three
cardiac cycles were captured for each measurement.
Two-dimensional images of the left ventricle were
acquired at sufﬁcient frame rate to allow measurement
of myocardial strain by speckle tracking from the four-
chamber view. Chamber sizes and systolic function were
measured according to the American Society of
Echocardiography (ASE) guidelines.19 Left ventricular
ejection fraction was measured using a biplane
Simpson’s method. Mitral inﬂow and pulmonary venous
ﬂow velocities were measured using pulsed wave
Doppler with the transducer positioned at the apex
according to the ASE guidelines.20 Mitral annular veloci-
ties were measured with the transducer at the apex and
with placement of the sample volume over the septal
and lateral mitral annulus. Peak systolic (S0), early dia-
stolic (E0) and late diastolic (A0) velocities were mea-
sured at the septal and lateral annulus, and averaged to
provide mean annular velocities. Strain and strain rate
were measured in the six-wall segments seen in the
apical four-chamber view using speckle tracking within
the EchoPAC software. The peak global strain and strain
rate are the peak values of the instantaneous mean of all
six segments. The mean peak systolic strain and strain
rate are the mean of the peak values in all segments and
were, therefore, not acquired at the same time due to
temporal variation between segments.
cIB was measured from a parasternal long axis view
with care taken to ensure the wall was perpendicular to
the transducer. Myocardial signal intensity was measured
at end diastole using a 4×8 mm region of interest within
the mid-wall of the basal anteroseptum and the basal
inferolateral wall, and from the posterior pericardium.
The cIB value was calculated by subtracting the pericar-
dial intensity from the average of the anteroseptal and
basal inferolateral wall intensities, and represents the
mean of two separate calculations performed 24 months
apart by the same investigator with an intraclass correl-
ation of 0.85 (95% CI 0.73 to 0.92, p<0.001). A
Bland-Altman plot for the two measurements of cIB is
shown in the online supplementary data.
Statistical analysis
Data are presented as means±SD for normally distribu-
ted variables and as medians with 25th and 75th centiles
for variables that were not normally distributed. The
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normality of continuous data was veriﬁed with the
Kolmogorov-Smirnov test and variables with a positively
skewed distribution were log transformed before analysis.
Correlations were estimated by univariable linear least
squares analysis, and Pearson or Spearman correlation
coefﬁcients were estimated. Differences were considered
signiﬁcant at two-tailed p<0.05.
RESULTS
Clinical characteristics
The clinical and biochemical characteristics of the
patient population are shown in table 1. Of the 40
patients (29 men and 11 women), 25 had no evidence
of previous myocardial infarction (no history of myocar-
dial infarction or pathological Q waves on ECG, akinesis
or dyskinesis on ventriculogram or echocardiography, or
scars visible on inspection of the heart at surgery); 9 had
recently documented non-ST-segment-elevation myocar-
dial infarction 5–89 days before surgery, and 6 had previ-
ous ST-segment elevation myocardial infarction before
surgery. Eleven patients (27.5%) were diabetic (1 type 1
and 10 type 2), 17 (42.5%) without diabetes had meta-
bolic syndrome, and 12 (30%) had neither diabetes nor
metabolic syndrome according to the International
Diabetes Federation criteria. All had extensive coronary
artery disease and received a median of 3 (range 2–5)
bypass grafts. Most were receiving recommended
cardiovascular therapies. Of the 40 patients, 39 (98%)
were receiving aspirin, 38 (95%) were receiving statins,
32 (80%) were receiving β-blockers, 29 (73%) were
receiving ACE inhibitors and/or angiotensin receptor
blockers, 11 (28%) were receiving calcium antagonists, 9
(23%) were receiving thiazides or indapamide, 9 (23%)
were receiving long-acting nitrates, and 2 (5%) were
receiving oral furosemide. None were receiving spirono-
lactone or eplerenone therapy.
Cardiac morphology and function
All patients were in sinus rhythm with an ejection frac-
tion >52% (table 2). Mean interventricular septal thick-
ness was 11±2 mm, posterior wall thickness was 10±2 mm
and left ventricular diastolic diameter was 47±6 mm.
Right ventricular function was normal in all participants.
Left atrial area was 23.3±4.4 cm², with 32 participants
having left atrial enlargement (area >20 cm²). Mean
right atrial area was 17.4±3.9 cm². Of the 39 participants
in whom diastolic function could be assessed, 22 had a
normal pattern, 12 had impaired relaxation and 5 had
pseudonormal ﬁlling.
Mean cIB for the 40 patients was −19.5±4.2 dB and
varied from −29 to −10 db. Mean cIB did not differ
between men (−19.4±3.9) and women (−19.8±5.1).
There were statistically signiﬁcant correlations between
cIB and log plasma amino-terminal-pro-B-type natriuretic
Table 1 Clinical and biochemical characteristics, and their correlation with calibrated integrated backscatter in 29 men and
11 women with coronary artery disease
Variable
Mean±SD or median
(IQR) (n=40) r p Value
Age (years) 65±11 0.31 0.053
Weight (kg) 83±13 0.003 0.99
Height (cm) 168±10 −0.05 0.75
Body surface area (m2) 1.9±0.2 −0.01 0.94
Body mass index (kg/m2) 30±6 0.02 0.90
Systolic blood pressure (mm Hg) 134±15 0.06 0.72
Diastolic blood pressure (mm Hg) 76±8 0.04 0.83
Pulse pressure (mm Hg) 58±14 0.04 0.80
Fasting plasma glucose (mmol/L) 6.0 (5.4–6.5)* −0.10† 0.53†
Fasting plasma insulin (pmol/L) 65 (36–108)* 0.02† 0.93†
β-cell function from HOMA2-%B 64 (52–110)* 0.08† 0.61†
Insulin sensitivity from HOMA2-%S 84 (51–139)* −0.008† 0.96†
Insulin resistance from HOMA2-IR 1.2 (0.8–2.0)* 0.004† 0.98†
Plasma NT-proBNP (pmol/L) 16 (7–32)* 0.34† 0.03†
Plasma creatinine (μmol/L) 87 (77–110)* 0.33† 0.04†
eGFR (mL/min/1.73 m2) 68±16 −0.33 0.04
Plasma C reactive protein (mg/L) 2.8 (0.7–7.2)* 0.03† 0.87†
Plasma PIP (μg/L) 284±78 0.07 0.68
Plasma PINP (μg/L) 32±14 0.01 0.95
Plasma PIIINP (μg/L) 2.5±1.1 0.03 0.84
eGFR is calculated from the Modification of Diet in Renal Disease formula.29
HOMA2-%B; HOMA2-%S and HOMA2-IR were calculated using the HOMA calculator V.2.2.30
*Median value and IQR given non-parametric distribution.
†Values derived from log-transformed data.
eGFR, estimated glomerular filtration rate; HOMA2-%B, β-cell function; HOMA2-IR, insulin resistance; HOMA2-%S, insulin sensitivity;
NT-proBNP, amino-terminal-pro-B-type natriuretic peptide; PIIINP, intact amino-terminal propeptide of type III procollagen; PINP, intact
amino-terminal propeptide of type 1 procollagen; PIP, carboxy-terminal propeptide of procollagen type I.
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peptide (NT-proBNP) level, plasma creatinine, estimated
glomerular ﬁltration rate (eGFR) (table 1), and mean
peak late diastolic annular velocity (A0) (table 2).
However, cIB was not signiﬁcantly correlated with plasma
levels of carboxy-terminal propeptide of procollagen type
I (PIP) or amino-terminal propeptides of procollagens
type 1 and III (PINP and PIIINP) (table 1).
Myocardial histology
The median area of the myocardial sections was 4.0
(25th and 75th centiles were 2.9 and 6.8, respectively)
mm2. Total ﬁbrosis, as assessed by picrosirius red stain-
ing, varied approximately 6-fold, from 0.7% to 4%, inter-
stitial ﬁbrosis varied 7.5-fold from 0.4% to 3%, and the
perivascular ﬁbrosis ratio varied 15-fold from 0.3 to 4.6.
cIB was weakly, but negatively correlated with log total
and log interstitial ﬁbrosis (ﬁgure 1), but was not corre-
lated with perivascular ﬁbrosis or any other histological
parameter, including immunostaining for collagens I
and III, advanced glycation end product (AGE)
Nε-(carboxymethyl)lysine (CML) and the receptor for
AGEs (RAGE) (table 3). Moreover, none of the other
echocardiographic parameters (table 2) or PIP, PINP or
PIIINP were signiﬁcantly correlated with log total or log
interstitial ﬁbrosis (data not shown).
Angiogenesis-related biomarkers
Of the plasma angiogenesis-related biomarkers evaluated
(table 4), log soluble vascular endothelial growth factor
receptor-1 (sVEGFR-1) and log soluble RAGE (sRAGE)
were associated with increased cIB (ﬁgure 2), but not
with capillary length density (data not shown).
None of the plasma angiogenesis-related biomarkers
evaluated (table 4) were correlated with total or intersti-
tial myocardial ﬁbrosis except for sRAGE, which was
negatively correlated with log total ﬁbrosis and log inter-
stitial ﬁbrosis using non-parametric Spearman correla-
tions (r=−0.36, p=0.04 for total ﬁbrosis; r=−0.50, p=0.005
for interstitial ﬁbrosis).
Table 2 Echocardiographic and haemodynamic characteristics, and their correlation with calibrated integrated backscatter in
29 men and 11 women with coronary artery disease
Variable
Mean±SD or median
(IQR) (n=30–40) r p Value
Left ventricular ejection fraction (%) 65±7 0.02 0.91
E/A ratio 1.06±0.35 −0.03 0.87
Mean S0 (cm/s) 7.4±1.5 0.03 0.87
Mean E0 (cm/s) 7.0±1.7 −0.06 0.70
Mean A’ (cm/s) 9.0±1.9 −0.32 0.048
Average E/E0 ratio 11.2±3.5 0.20 0.22
Peak global systolic strain (%) −18.6±2.8 0.14 0.45
Peak global systolic strain rate (s−1) −0.97±0.17 0.13 0.49
Mean peak systolic strain (%) −19.2±2.8 0.10 0.60
Mean peak systolic strain rate (s−1) −1.21±0.44 −0.14 0.47
Calculated integrated backscatter (dB) −19.5±4.2
Central venous pressure (mm Hg) 7.8±3.4 −0.21 0.20
Pulmonary capillary wedge pressure (mm Hg) 10 (8–12)* −0.24† 0.13†
Cardiac index (L/min/m2) 2.6±0.6 0.17 0.30
Data shown for 40 patients, except for strain and strain rate where n=30–31 patients.
Central venous pressure, pulmonary capillary wedge pressure, and cardiac index were measured immediately postinduction of anaesthesia.
*Median value and IQR given non-parametric distribution.†Value derived from log-transformed data.
Figure 1 Correlation of calibrated integrated backscatter
(cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis
(B) in patients undergoing coronary artery bypass graft
surgery, n=40. The correlations of cIB with log10 total and
interstitial fibrosis were also statistically significant using
non-parametric Spearman correlations (r=−0.32, p=0.04 for
total fibrosis; r=−0.39, p=0.01 for interstitial fibrosis).
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DISCUSSION
The present study is the ﬁrst to report the association
between cIB and myocardial ﬁbrosis in patients without
extensive ﬁbrosis. In contrast to previous studies of
patients with dilated or hypertrophic cardiomyopathy
and mean myocardial ﬁbrosis of 15–34%,1–5 we found
that cIB was weakly but inversely associated with myocar-
dial ﬁbrosis of 0.7–4%, as assessed by picrosirius red
staining. However, cIB was not signiﬁcantly associated
with other histological parameters, including
Table 3 Left ventricular histological parameters and their correlation with calibrated integrated backscatter values in 29 men
and 11 women with coronary artery disease
Variable
Mean±SD or median
(IQR) (n=40) r p Value
Total fibrosis (%) 1.8 (1.2–2.6)* −0.32† 0.047†
Interstitial fibrosis (%) 1.3 (0.9–1.7)* −0.34† 0.03†
Perivascular fibrosis ratio 1.7 (1.1–2.3)* −0.12† 0.49†
Arterioles/mm2 myocardium area 0.8±0.4 −0.02 0.90
Mean arteriolar diameter (μm) 40±12 −0.17 0.31
Arteriolar wall area/circumference ratio (μm2/μm) 5.5±1.7 −0.07 0.66
Cardiomyocyte width (μm) 22±3 −0.26 0.11
Capillary length density (mm/mm3) 1106±419 0.11 0.51
Diffusion radius (μm) 18±4 −0.12 0.47
Collagen I total fibrosis (%) 5.0±3.9 0.06 0.74
Collagen I interstitial fibrosis (%) 2.4±2.8 0.08 0.61
Collagen III total fibrosis (%) 10.0±4.6 −0.03 0.86
Collagen III interstitial fibrosis (%) 7.4±4.0 −0.02 0.92
Total collagen I/III ratio 0.57±0.46 0.12 0.48
Interstitial collagen I/III ratio 0.35±0.27 0.11 0.51
CML immunostaining arteriole media 1.6±0.8 0.15 0.36
CML immunostaining arteriole intima 1.8±0.7 0.07 0.65
RAGE immunostaining arteriole media 0.6±0.7 −0.14 0.41
RAGE immunostaining arteriole intima 1.6±0.8 −0.11 0.49
RAGE immunostaining capillaries 1.3±1.0 0.07 0.68
*Median value and IQR given non-parametric distribution.
†Values derived from log-transformed data; n=40, except for perivascular fibrosis where n=38, and for capillary length density and diffusion
radius where n=39; arteriolar wall area/circumference ratio was measured for arterioles with diameter (average of maximum and minimum
diameter of each arteriole) of 20–80 μm.
CML, Nε-(carboxymethyl)lysine; RAGE, receptor for advanced glycation end products.
Table 4 Plasma concentrations of angiogenesis-related biomarkers and their correlation with calibrated integrated
backscatter values in 29 men and 11 women with coronary artery disease
Variable
Mean±SD or median (IQR)
(n=33–40) r p Value
VEGF-A (pg/mL) 22 (13–33)* −0.17† 0.34†
sVEGFR-1 (pg/mL) 90 (64–131)* 0.44† 0.01†
sVEGFR-2 (ng/mL) 6.5±1.1 0.07 0.70
Angiopoietin-1 (ng/mL) 3.5 (2.0–4.5)* −0.30† 0.09†
Angiopoietin-2 (ng/mL) 1.4 (1.2–1.9)* 0.29† 0.10†
Tie-1 (ng/mL) 36±9 0.04 0.82
Tie-2 (ng/mL) 15±4 0.14 0.44
Fibroblast growth factor basic (pg/mL) 6.8±2.9 −0.03 0.85
Endostatin (ng/mL) 99±44 0.16 0.38
Placental growth factor (pg/mL) 11±4 0.32 0.07
Hepatocyte growth factor (pg/mL) 850 (622–969)* 0.26† 0.14†
Nε-(carboxymethyl)lysine (μmol/L) 1.8±0.6 0.12 0.46
LMWF (AU/mL) 2.3 (1.5–3.3)* 0.08† 0.61†
sRAGE 527 (456–937)* 0.53† 0.002†
*Median value and IQR given non-parametric distribution.
†Values derived from log-transformed data; n=40 for Nε-(carboxymethyl)lysine and LMWF levels, and n=33 for all other angiogenesis-related
biomarkers.
LMWF, low-molecular-weight fluorophore; sRAGE, soluble receptor for advanced glycation end products; VEGF, vascular endothelial growth
factor; sVEGFR, soluble VEGF receptor.
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immunostaining for collagens I and III, CML and
RAGE. In addition, cIB was weakly associated with
plasma levels of NT-proBNP, creatinine and eGFR, and
more strongly associated with plasma sVEGFR-1 and
sRAGE levels. We previously demonstrated less myocar-
dial ﬁbrosis in women than in men undergoing CABG
surgery,18 and increased myocardial interstitial ﬁbrosis in
patients with aortic stenosis than in patients with CABG
surgery without aortic stenosis.21 The present ﬁndings
suggest that higher cIB values cannot be used as a surro-
gate measure of greater myocardial ﬁbrosis in patients
without dilated or hypertrophic cardiomyopathy and
extensive ﬁbrosis, and that potential surrogate markers
of myocardial ﬁbrosis need to be validated in different
patient populations.
Although cIB is a measure of reﬂectance of the ultra-
sound signal by the myocardium, there is uncertainty
about the determinants of cIB. The cIB values we mea-
sured were similar to those reported by Jellis et al17 in a
group of patients with early diabetic cardiomyopathy;
their ﬁnding of only a borderline correlation between T1
values and cIB (p=0.053) is in agreement with our
ﬁnding that higher cIB values were not a marker of
greater ﬁbrosis in patients without extensive ﬁbrosis.
Taken together with previous reports,1–5 our data suggest
that the contribution of ﬁbrosis to cIB depends on the
extent of ﬁbrosis and other factors play a greater role in
determining cIB when ﬁbrosis is less extensive. This may
result in a threshold level of ﬁbrosis below which cIB is
not positively related to ﬁbrosis, but above which it may
be a useful measure. It is also possible that in previous
studies, the observed relationship between cIB and ﬁbro-
sis was, in fact, mediated by another property, and that
this relationship was lost with less-extensive ﬁbrosis. Our
ﬁnding that cIB was associated with plasma NT-proBNP,
creatinine and eGFR suggests that cIB is inﬂuenced by
ﬂuid status, and this is in agreement with previous
reports that cIB is correlated with serum creatinine in
patients with chronic renal failure12 and is reduced by
increased hours/week of dialysis over 12 months.13
The mechanism of the associations between cIB and
plasma levels of sVEGFR-1 and sRAGE is not known.
Increased plasma levels of sVEGFR-1 are associated with
disease severity and adverse outcomes in chronic heart
failure,22 and plasma sRAGE levels are associated with
coronary events and cardiovascular mortality in dia-
betes.23 24 Thus, the basis of the association of plasma
sVEGFR-1 and sRAGE levels with cIB may be similar to
the association of acute myocardial ischaemia and acute
cardiac allograft rejection with cIB.9 10 sVEGFR-1 func-
tions as a VEGF-A antagonist by preventing VEGF-A
binding to VEGFR-2, the main VEGFR-mediating angio-
genesis, and may thereby inhibit angiogenesis. It is also
possible that the association of plasma levels of sVEGFR-1
and sRAGE with cIB has a similar basis to the reported
association of plasma IL-13 levels with cIB in patients with
idiopathic dilated cardiomyopathy.11 IL-13 causes anti-
inﬂammatory activities,25 and angiogenic and antiangio-
genic activities have been reported for this cytokine.26 27
However, the failure of either sVEGFR-1 or sRAGE to cor-
relate with myocardial capillary length density suggests
that these markers represent mechanisms of myocardial
reﬂectivity that are unrelated to angiogenesis.
There is uncertainty about the relevance of circulating
collagen-derived peptides to cardiac ﬁbrosis because
these result from collagen turnover in many different
tissues other than the heart.28 It is, therefore, not sur-
prising that we found no correlation between PIP, PINP
and PIIINP levels and either cIB or myocardial total or
interstitial ﬁbrosis. Jellis et al17 reported that PIIINP, but
not PINP or PIP, was correlated with cIB; however, none
were correlated with the postcontrast T1 value.
Study limitations
This was necessarily a cross-sectional study that provided
limited information about the mechanisms of myocardial
reﬂectivity because of the impossibility of obtaining serial
myocardial biopsies, and our study was limited to 40 parti-
cipants given the difﬁculty of obtaining myocardial biop-
sies in patients who were well characterised clinically,
biochemically, haemodynamically and with cardiac
imaging. This number of patients is, however, greater than
the number studied in previous studies,1–3 5 except for the
study of dilated cardiomyopathy by Mizuno et al.4
Moreover, we studied biopsies from the same subepicardial
Figure 2 Correlations of calibrated integrated backscatter
(cIB) with log10 plasma soluble vascular endothelial growth
factor receptor-1 (sVEGFR-1) (A), and log10 plasma soluble
receptor for advanced glycation end products (sRAGE) (B) in
patients undergoing coronary artery bypass graft surgery,
n=33. The correlations of cIB with log10 sVEGFR-1 and log10
sRAGE were also statistically significant using non-parametric
Spearman correlations (r=0.41, p=0.02 for sVEGFR-1; r=0.40,
p=0.02 for sRAGE).
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region of the left ventricular myocardium in all patients
and we do not know if the histology of these biopsies was
representative of the regions used to estimate cIB.
Although the patients had extensive coronary artery
disease, we biopsied a region of myocardium that was free
of ischaemia, without wall motion abnormalities; the hist-
ology of the biopsies showed no evidence of ischaemia or
replacement ﬁbrosis. We cannot exclude the possibility
that myocardial interstitial and perivascular ﬁbrosis were
inhomogeneous, but our data clearly provide no support
for a positive relationship between cIB and myocardial
ﬁbrosis in this patient population. Future studies are neces-
sary to directly compare myocardial histology with alterna-
tive non-invasive methods of evaluation myocardial
ﬁbrosis, such as T1 mapping by cardiac MRI,17 and to
investigate the relationships between cIB and plasma levels
of NT-proBNP, creatinine, eGFR, sVEGFR-1 and sRAGE.
CONCLUSION
This study demonstrates that the positive association
between cIB and myocardial ﬁbrosis in patients with
dilated or hypertrophic cardiomyopathy and extensive
ﬁbrosis cannot be extrapolated to patients with coronary
artery disease without extensive ﬁbrosis; by contrast, we
found a weak inverse association between cIB and myo-
cardial ﬁbrosis in this patient population. cIB also
showed weak associations with plasma levels of
NT-proBNP, creatinine and eGFR, and stronger associa-
tions with plasma sVEGFR-1 and sRAGE levels. The role
of cIB as a non-invasive index of ﬁbrosis in clinical
studies of patients with early myocardial disease without
extensive ﬁbrosis is, therefore, questionable.
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